FMC Corporation FMC has submitted a regulatory dossier for rimisoxafen to Brazilian authorities, marking the second global regulatory submission for the herbicide following its filing with the U.S. Environmental Protection Agency in July 2026. The filing advances FMC’s efforts to develop next-generation crop protection solutions and bring them to major agricultural markets.
Brazil is one of the world’s largest soybean and corn producers, with more than 50 million hectares of soybeans and more than 20 million hectares of corn under cultivation. Growers are increasingly dealing with resistant broadleaf weeds, including Amaranthus hybridus and Amaranthus palmeri , creating demand for newer methods to enhance crop productivity.
The Herbicide Resistance Action Committee classified rimisoxafen under Groups 12 and 32. Being the first dual mode of action herbicide, its field testing has demonstrated consistent activity against small-seeded broadleaf weeds, including those resistant to other herbicides. The product could therefore help growers diversify weed management programs and support resistance management.
Rimisoxafen is the third novel herbicide active ingredient FMC has advanced to regulatory submission in Brazil, following Isoflex and Dodhylex. These product submissions represent FMC’s depth and productivity in the R&D pipeline and are expected to advance as the regulatory process progresses. However, rimisoxafen remains subject to regulatory review and approval and is not currently registered for sale or use in Brazil or any other country.
FMC shares have slumped 72.6% in the past year compared with the industry’s 10% growth in the same period.
Image Source: Zacks Investment Research
FMC’s Zacks Rank & Key Picks
FMC currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the Basic Materials space are Reliance, Inc. RS, Avient Corporation AVNT and Kronos Worldwide, Inc. KRO.
RS, AVNT and KRO carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for RS’ 2026 earnings is pegged at $22.53 per share, indicating a 58% year-over-year increase. RS’ shares have gained 39.4% over the past year.
The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.2 per share, indicating a 13.5% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’s shares have gained 25% over the past year.
The Zacks Consensus Estimate for KRO’s 2026 earnings is pegged at 35 cents per share, indicating a rise of 136.5% year over year. Its earnings beat the Zacks Consensus Estimate in two of the trailing four quarters while missing it in the rest, with an average surprise of 34%.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
FMC Corporation (FMC): Free Stock Analysis Report
Reliance, Inc. (RS): Free Stock Analysis Report
Kronos Worldwide Inc (KRO): Free Stock Analysis Report
Avient Corporation (AVNT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).